First of its kind 'J-Valve' surgery performed at Christ Hospital

A first-of-its-kind surgery is being performed as part of a clinical trial at The Lindner Research Center.The minimally invasive surgery is designed to treat severe native aortic regurgitation and AR-dominant mixed aortic valve disease in patients.The successful procedure was done by Dr. Dean Kereiakes, Dr. Santiago Garcia and the team at The Lindner Research Center at The Christ Hospital Health Network earlier this month.Enrollment for the early feasibility study using the device was announced through a partnership between the Christ Hospital Heart & Vascular Institute and Genesis MedTech, a medical device company. The J-Valve TF System, which was developed by JC Medical, is regarded as a valve that addresses unmet clinical need and has potential to help many, as described by Dr. Garcia, principle investigator for the study at The Christ Hospital Health Network. "Unlike cardiac surgery, our patient did not have general anesthesia and went home the next day," Garcia added. "We are pleased to report that the first Early Feasibility case using a 34mm J-Valve yielded favorable results," Kereiakes, president of the Christ Hospital Heart and Vascular Institute and National Co-Principal Investigator for the study said in a statement. "The J-Valve TF System could potentially revolutionize the treatment of aortic regurgitation, allowing larger annular sizes to be treated." The completion of the implantation is a milestone moment for Genesis MedTech."This achievement demonstrates our dedication to advancing medical technology in the structural heart disease sector. Collaborating with leading TAVR sites across the US and Canada, we hope to demonstrate results that will highlight the unique ability of a dedicated TAVR valve like J-Valve in treating patients with a life-threatening disorder." The North American EFS is part of a broad clinical program that will investigate the treatment of patients with aortic regurgitation," Dr. Mark A. Turco, CEO JC Medical and President of Vascular Intervention North America at Genesis MedTech shared, said in a statement.